ClinicalTrials.gg
CompletedNCT00252564Updated Feb 15, 2019Results posted

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

A Phase 3 interventional study of Bevacizumab and Oxaliplatin in Metastatic Colorectal Cancer, sponsored by US Oncology Research. Completed at 82 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Enrollment
35th of 183
247 · median 50
Started
2005
with 14 others
Phase 3
36 of 206
4 open now
Registered
64th of 206
by date

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 35th largest by enrollment of the 183 interventional ones that give a count, is one of 15 that started in 2005, is one of 36 in phase 3, and was the 64th registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.

Read the detailed description

This is a Phase III, open label, nonblinded study. A total of 240 eligible patients will be randomized on a 1:1 basis to either treatment Arm.

In this trial, we will compare the efficacy, safety, and tolerability of this novel combination of biweekly infusional 5-FU/leucovorin plus cetuximab and bevacizumab (FOLF-CB) to the current standard of care, biweekly infusional 5-FU/leucovorin plus oxaliplatin and bevacizumab (Bev-FOLFOX). For practical purposes, this study will be a head to head comparison of oxaliplatin versus cetuximab, since the other components of both regimens will be the same.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed colorectal cancer with disease
  • Previously irradiated lesions will be considered evaluable, if they progressed since radiation
  • Has disease other than limited to surgically resectable liver-only or lung-only metastatic disease
  • Not received prior chemo and/or biotherapy for metastatic disease
  • Not received oxaliplatin, bevacizumab, or cetuximab in the setting
  • May have received 5-FU, leucovorin, and/or irinotecan in the adjuvant setting, however must have remained free of disease recurrence (including free of abnormal CEA level) for 1- year or more
  • Is >18 years of age
  • performance status 0 or 1
  • Normal organ \& marrow function
  • Use of an acceptable method of
  • Not pregnant or breast feeding
  • Paraffin tissue block(s) or 12 (minimum) unstained slides available, for assessment of potential predictive markers related to the EGFR, VEGF, DNA repair, and fluoropyrimidine catabolism pathways. If no block is available, slides (typically 7 to 10 um sections, air dried on uncharged slides) may be sent
  • Signed a Patient Form
  • Signed a Patient Authorization Form (HIPAA) Form

Exclusion criteria

EXCLUSION CRITERIA:

  • Had prior chemotherapy for colorectal cancer
  • Received any prior treatment with oxaliplatin, bevacizumab, or cetuximab in the treatment of their colorectal cancer
  • Currently receiving any other anticancer agents or has participated in an experimental drug study within the past 4 weeks
  • History of primary CNS tumors, seizures not well-controlled with standard medical therapy, or stroke
  • Sustained hypertension, as characterized by persistent blood pressures greater than 150/100 despite medical management
  • (NYHA) Grade II or greater congestive heart failure or has had angioplasty or placement of coronary stents within the past 6 months
  • peripheral vascular disease
  • History of serious allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, cetuximab, oxaliplatin, fluorouracil, leucovorin, or other agents used in the study
  • Received prior cetuximab or other EGFR-directed therapy, or history of prior anti-cancer murine or chimeric monoclonal antibody therapy; prior humanized and human monoclonal antibody therapy is also excluded.
  • Received prior treatment with bevacizumab or other agents specifically targeting VEGF or VEGF receptors
  • Uncontrolled intercurrent illness including, not limited to, ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, uncontrolled hypertension, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the Investigator/Treating Physician
  • Serious or non-healing active wound ulcer, or active bone fracture
  • Major surgical procedure, open , or significant traumatic injury within 28 days prior to Day 1 of protocol treatment
  • Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 1
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
  • Current or recent use of a thrombolytic agent within last 30 days. Use for clearance of central line catheter is permitted.
  • Evidence of bleeding diathesis (disorder) or clinically significant coagulopathy (Note that deep venous thrombosis is not regarded as a reason for exclusion from this trial)
  • to Chinese hamster ovary cell products or other recombinant human antibodies
  • History of arterial thromboembolic events within 6 months
  • Urine protein:creatinine ratio greater than 1.0 at screening
  • Pregnant or lactating woman
  • Known to be positive or receiving combination anti-retroviral therapy
  • Unable to comply with study requirements
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Bev-FOLFOX

    (Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via "T" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU. Bevacizumab --\> oxaliplatin and LV --\> bolus 5-FU --\> infusional 5-FU Dosing on Days 1 and 15 of each 28-day cycle

    Drug: Bevacizumab · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil

  • Experimental
    FOLF-CB

    (FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU. Cetuximab --\> bevacizumab --\> LV --\> bolus 5-FU --\> infusional 5-FU

    Drug: Bevacizumab · Drug: Leucovorin · Drug: Fluorouracil · Drug: Cetuximab

Interventions

  • 5 mg/kg over 30 minutes on Days 1 and 15

    Also known as: Avastin

  • 85 mg/m2 on Days 1 and 15

    Also known as: Eloxatin

  • 400 mg/m2 on Days 1 and 15

  • 400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)

    Also known as: 5FU

  • 400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour

    Also known as: Erbitux

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring). Kaplan-Meier median PFS time and PFS rate (at 12 months)

    Time frame: 12 months

  2. Progression-free Survival (PFS) Rate at 1 Year.

    From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).

    Time frame: 12 months

Secondary outcomes

  1. Overall Survival (OS)

    From randomization to death (event); or last follow-up date if alive (censoring). Kaplan-Meier OS median time.

    Time frame: up to 4 years

  2. Objective Response Rate

    Percentage of patients with tumor response (by RECIST criteria, including complete response, or CR, i.e. disappearance of all target lesions; and partial response, or PR, i.e. at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of the longest diameters) among all "per-protocol population" patients.

    Time frame: 12 months

07

Results

Posted Mar 14, 2011

Participant flow

A total of 247 patients were recruited from multiple research sites and were randomly assigned to either Arm A or Arm B between December 2005 to June 2007.

Participant flow — Overall Study
MilestoneArm AArm B
Started124123
Completed8579
Not completed3944
Withdrew: Adverse event1713
Withdrew: Unrelated complication21
Withdrew: Disease progression1420
Withdrew: Death03
Withdrew: Physician decision10
Withdrew: Lost to follow-up10
Withdrew: Patient request45
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryProgression-Free Survival (PFS)

From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring). Kaplan-Meier median PFS time and PFS rate (at 12 months)

Time frame:
12 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsArm AArm B
Progression-Free Survival (PFS)11.0 (9.2 to 13.6)8.3 (6.7 to 9.7)
PrimaryProgression-free Survival (PFS) Rate at 1 Year.

From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).

Time frame:
12 months
Reported as:
Number · proportion of participants w/ PFS at 1yr
Progression-free Survival (PFS) Rate at 1 Year.
proportion of participants w/ PFS at 1yrArm AArm B
Progression-free Survival (PFS) Rate at 1 Year.0.45 (0.34 to 0.55)0.32 (0.23 to 0.42)
SecondaryOverall Survival (OS)

From randomization to death (event); or last follow-up date if alive (censoring). Kaplan-Meier OS median time.

Time frame:
up to 4 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm AArm B
Overall Survival (OS)21.3 (18.2 to 25.2)19.5 (16.5 to 21.6)
SecondaryObjective Response Rate

Percentage of patients with tumor response (by RECIST criteria, including complete response, or CR, i.e. disappearance of all target lesions; and partial response, or PR, i.e. at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of the longest diameters) among all "per-protocol population" patients.

Time frame:
12 months
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsArm AArm B
Objective Response Rate52.1 (42.7 to 61.5)41.2 (32.2 to 50.6)

Adverse events

Collected over during the whole treatment period, up to 30 days following last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A—40/118 (33.9%)117/118 (99.2%)
Arm B—49/121 (40.5%)120/121 (99.2%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventArm AArm B
DEHYDRATIONGastrointestinal disorders3/1187/121
THROMBOSISVascular disorders4/1187/121
INTESTINAL OBSTRUCTIONGastrointestinal disorders2/1184/121
SEPSISInfections and infestations1/1184/121
BOWEL OBSTRUCTIONGastrointestinal disorders3/1181/121
DIARRHEAGastrointestinal disorders3/1183/121
FEBRILE NEUTROPENIAInfections and infestations3/1180/121
ABDOMINAL PAINGastrointestinal disorders0/1183/121
CHEST PAINRespiratory, thoracic and mediastinal disorders0/1183/121
PNEUMONIARespiratory, thoracic and mediastinal disorders0/1183/121
Most frequent other events
Showing 10 of 63
Most frequent other events
EventArm AArm B
RASHSkin and subcutaneous tissue disorders17/11883/121
NEUROPATHYNervous system disorders68/11814/121
NAUSEAGastrointestinal disorders59/11854/121
FATIGUEGeneral disorders55/11840/121
DIARRHEAGastrointestinal disorders53/11850/121
NEUTROPENIABlood and lymphatic system disorders49/11819/121
ANEMIABlood and lymphatic system disorders45/11828/121
THROMBOCYTOPENIABlood and lymphatic system disorders42/11822/121
LEUKOPENIABlood and lymphatic system disorders37/11826/121
CONSTIPATIONGastrointestinal disorders30/11836/121

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm AArm BTotal
<=18 years000
Between 18 and 65 years7367140
>=65 years5156107
Age, Continuous
Age, Continuous(years)Arm AArm BTotal
Mean61 ± 1263 ± 1162 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female5450104
Male7073143
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm AArm BTotal
American Indian or Alaska Native202
Asian336
Native Hawaiian or Other Pacific Islander000
Black or African American151530
White10099199
More than one race000
Unknown or Not Reported4610
Region of Enrollment
Region of Enrollment(participants)Arm AArm BTotal
United States124123247
08

Study locations

82 sites
  • Brimingham Hematology and Oncology
    Birmingham, Alabama 35235, United States
  • Hematology Oncology Associates
    Phoenix, Arizona 85012, United States
  • Northern AZ Hematology & Oncology Assoc
    Sedona, Arizona 86336, United States
  • Business Office - ACRC
    Tucson, Arizona 85715, United States
  • Cancer Care Associates of Fresno Medical Group, Inc (aka California Cancer Care)
    Fresno, California 93720, United States
  • Monterey Bay Oncology
    Monterey, California 93940, United States
  • Rocky Mountain Cancer Center-Midtown
    Denver, Colorado 80218, United States
  • Greeley Medical Clinic Oncology Hematology, PC
    Greeley, Colorado 80538, United States
  • Connecticut Oncology & Hematology, LLP
    Torrington, Connecticut 06790, United States
  • Integrated Community Oncology Network (ICON) / fka:Florida Oncology Associates
    Jacksonville, Florida 32204, United States
  • Melbourne Internal Medicine Associates
    Melbourne, Florida 32901, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34655, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • Medical Oncology Associates of Augusta PC
    Augusta, Georgia 30901, United States
  • Spalding Oncology Services
    Griffin, Georgia 30224, United States
  • Hematology Oncology Associates of IL
    Chicago, Illinois 60611, United States
  • Cancer Care & Hematology Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Fort Wayne Medical Oncology Hematology, Inc
    Fort Wayne, Indiana 46815, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46219, United States
  • Hope Center
    Terre Haute, Indiana 47802, United States
  • Iowa Blood and Cancer Care
    Cedar Rapids, Iowa 52402, United States
  • Kansas City Cancer Centers-Southwest
    Overland Park, Kansas 66210, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Louisiana Hematology Oncology Associates
    Baton Rouge, Louisiana 70809, United States
  • Auerbach Hematology Oncology Associated
    Baltimore, Maryland 21237, United States
  • Center for Cancer & Blood Disorders
    Bethesda, Maryland 20817, United States
  • Maryland Oncology Hematology, P.A.
    Columbia, Maryland 21044, United States
  • Osteopathic Medical Oncology and Hematology
    Clinton Township, Michigan 48037, United States
  • Kalamazoo Hematology & Oncology
    Kalamazoo, Michigan 49048, United States
  • Hematology Oncology Associates of Ohio & Michigan
    Lambertville, Michigan 48144, United States
  • Minnesota Oncology Hematology, PA
    Minneapolis, Minnesota 55404, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89109, United States
  • Nevada Cancer Centers
    Las Vegas, Nevada 89109, United States
  • Hematology-Oncology Associates of NNJ, PA
    Morristown, New Jersey 07960, United States
  • New York Oncology Hematology, PC
    Albany, New York 12208, United States
  • North Shore Hematology
    East Setauket, New York 11733, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10017, United States
  • Raleigh Hematology Oncology Associates
    Cary, North Carolina 27511, United States
  • Northwestern Carolina Ocology Hemato
    Hickory, North Carolina 28602, United States
  • Greater Dayton Cancer Center
    Kettering, Ohio 45409, United States
  • Willamette Valley Cancer Center
    Eugene, Oregon 97401, United States
  • Medical Oncology Associates
    Kingston, Pennsylvania 18704, United States
  • Cancer Center Associates of Carolina, PA / fka Carolina Cancer Center
    Aiken, South Carolina 29801, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • C. Michael Jones, MD
    Germantown, Tennessee 38138, United States
  • Texas Cancer Center-Abilene (Shouth)
    Abilene, Texas 79606, United States
  • Texas Cancer Center
    Arlington, Texas 76014, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702, United States
  • Texas Oncology, PA - Bedford
    Bedford, Texas 76022, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230, United States
  • Texas Oncology, PA
    Dallas, Texas 75231, United States
  • The Texas Cancer Center
    Dallas, Texas 75237, United States
  • Texas Oncology, PA
    Dallas, Texas 75246, United States
  • Texas Cancer Center-Denton
    Denton, Texas 76210, United States
  • El Paso Cancer Treatment Ctr
    El Paso, Texas 79915, United States
  • Texas Oncology, PA
    Fort Worth, Texas 76104, United States
  • San Antonio Tumor & Blood Clinic
    Fredericksburg, Texas 78624, United States
  • Texas Oncology, PA
    Garland, Texas 75042, United States
  • Lake Vista Cancer Center
    Lewisville, Texas 75067, United States
  • Longview Cancer Center
    Longview, Texas 75601, United States
  • South Texas Cancer Center-McAllen
    McAllen, Texas 78503, United States
  • Texas Cancer Center of Mesquite
    Mesquite, Texas 75150, United States
  • Allison Cancer Center
    Midland, Texas 79701, United States
  • West Texas Cancer Center
    Odessa, Texas 79761, United States
  • Paris Regional Cancer Center
    Paris, Texas 75460, United States
  • HOAST - Medical Dr.
    San Antonio, Texas 78229, United States
  • Texas Cancer Center-Sherman
    Sherman, Texas 75090, United States
  • Texas Oncology Cancer Center-Sugar Land
    Sugar Land, Texas 77479, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Waco Cancer Care and Research Center
    Waco, Texas 76712, United States
  • Texas Oncology, P.A.
    Webster, Texas 77598, United States
  • Texas Oncology, PA
    Webster, Texas 77598, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Puget Sound Cancer Center-Edmonds
    Edmonds, Washington 98026, United States
  • Puget Sound Cancer Center Seattle
    Seattle, Washington 98133, United States
  • Cancer Care Northwest-South
    Spokane, Washington 99202, United States
  • Northwest Cancer Specialists-Vancouver
    Vancouver, Washington 98684, United States
  • Yakima Valley mem Hosp/North Star Lodge
    Yakima, Washington 98902, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Jun 2007 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2005
First posted
Nov 11, 2005
Start
Sep 2005
Primary completionActual
Jun 2007
CompletionActual
Jun 2009
Results first posted
Mar 14, 2011
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00252564
Collaborators
Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center, Prologue Research International
Responsible party
Sponsor
First posted
Nov 11, 2005
Start date
Sep 2005
Primary completion
Jun 2007
Completion
Jun 2009
Results posted
Mar 14, 2011
Last update
Feb 15, 2019

Study contacts

Allen Cohn, MD
principal investigator · US Oncology Research
Leonard Saltz, M.D.
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Cetuximab

Start the discussion